Basal cell carcinoma - Karsinoma Sél Basal
☆ Dina hasil Stiftung Warentest 2022 ti Jerman, kapuasan konsumen sareng ModelDerm ngan ukur langkung handap tibatan konsultasi telemedicine anu mayar.
Lesions borok mangaruhan kulit irung dina individu manula mindeng didiagnosis salaku Karsinoma Sél Basal (Basal cell carcinoma). Irung mangrupikeun tempat umum pikeun jenis kanker kulit ieu.
Karsinoma Sél Basal (Basal cell carcinoma) tiasa hadir sareng wates anu henteu teratur sareng borok.
Karsinoma Sél Basal (Basal cell carcinoma) tiasa disalahartikeun ku kutil.
References
Basal cell carcinoma (BCC) mangrupikeun jinis kanker kulit anu paling umum. Paparan sinar panonpoé mangrupikeun panyabab utama. Ampir sadaya kasus BCC nunjukkeun sinyal Landak overactive dina analisis molekular. Pangobatan anu béda-béda sayogi sareng dipilih dumasar kana résiko kambuh, pentingna pelestarian jaringan, karesep pasien, sareng tingkat panyakit.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas mangrupikeun jinis kanker kulit anu paling umum dina déwasa anu kulitna adil yuswa 50 taun ka luhur. Jumlahna naék di sakuliah dunya, utamina kusabab paparan sinar panonpoé. Kaayaan genetik anu tangtu tiasa ngajantenkeun jalma rawan ngembangkeun kanker ieu dina umur anu langkung ngora. Basal cell carcinomas rupa-rupa severity, mimitian ti lesions deet atawa nodular gampang diubaran nepi ka leuwih éksténsif anu merlukeun diskusi dina tim médis husus. Prognosis gumantung kana kamungkinan kanker balik deui atanapi kamampuanna ngarusak jaringan caket dieu. Bedah mangrupikeun perlakuan standar pikeun kalolobaan kasus, mastikeun panyabutan tepat sareng kamungkinan kambuh. Métode kirang invasif bisa éféktif ngubaran lesions deet.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Perawatan primér pikeun BCC nyaéta bedah. Pikeun BCC anu résiko luhur atanapi kambuh, khususna di daérah kritis, bedah anu dikontrol sacara mikrografi disarankeun. Pasén kalawan BCC deet resiko low bisa mertimbangkeun perlakuan topical atawa métode destructive. Terapi Photodynamic jalan ogé pikeun BCCs nodular deet sarta-resiko low. Pikeun BCC maju atanapi métastatik lokal, sambetan Landak (vismodegib, sonidegib) disarankeun. Upami aya kamajuan panyakit atanapi intoleransi kana sambetan Landak, imunoterapi sareng anti-PD1 antibody (cemiplimab) tiasa dipertimbangkeun. Radioterapi mangrupikeun pilihan anu saé pikeun pasien anu henteu tiasa dioperasi, khususna pasien anu langkung sepuh. Electrochemotherapy bisa dianggap lamun bedah atawa radiotherapy teu hiji pilihan.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Faktor résiko kalebet paparan sinar ultraviolét, terapi radiasi, paparan jangka panjang ka arsénik sareng fungsi sistem imun anu goréng (misalna cangkok organ). Paparan sinar UV nalika budak leutik hususna ngabahayakeun.
Saatos diagnosa ku biopsy, perlakuan biasana ku jalan ngaleupaskeun bedah. Ieu tiasa ku excision basajan lamun kanker leutik; Upami kanker henteu sakedik, bedah Mohs umumna disarankeun.
Karsinoma sél basal nyababkeun sahenteuna 32% tina sadaya kanker sacara global. Tina kangker kulit lian ti melanoma, sakitar 80% mangrupikeun kangker sél basal. Di Amérika Serikat, sakitar 35% lalaki bodas sareng 25% awéwé bodas kapangaruhan ku karsinoma sél basal di sawatara titik dina kahirupan maranéhanana.
○ Diagnosis sareng Perawatan
#Dermoscopy
#Skin biopsy
#Mohs surgery